Cambrex Corp (CBM):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Cambrex Corp (CBM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C5330)・商品コード:DATA904C5330
・発行会社(調査会社):GlobalData
・発行日:2018年9月
・ページ数:40
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Cambrex Corp (Cambrex) is a life science company that focuses on the development and commercialization of small molecule therapeutics. The company’s major products include active pharmaceutical ingredients (APIs), advanced intermediates and drug delivery products for branded and generic pharmaceuticals. It serves various generic drug companies and companies that discovers and commercializes small molecule human therapeutics using organic chemistry. Cambrex has its R&D and manufacturing facilities in the US and Europe. The company markets its products directly and also through a network of independent agents across Europe, North America and Asia, among others. Cambrex is headquartered in East Rutherford, New Jersey, the US.

Cambrex Corp (CBM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cambrex Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cambrex Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Cambrex Corp, Pharmaceuticals & Healthcare, Deal Details 9
Acquisition 9
Cambrex to Acquire Halo Pharma from SK Capital Partners for USD425 Million 9
Cambrex Acquires PharmaCore for USD24.275 Million 11
Cambrex Acquires 100% Stake in Zenara Pharma 12
Cambrex Corp – Key Competitors 13
Cambrex Corp – Key Employees 14
Cambrex Corp – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Recent Developments 16
Strategy And Business Planning 16
Sep 26, 2017: Cambrex opens API manufacturing facility and invests in supporting waste water treatment plant at its Karlskoga, Sweden site 16
Aug 08, 2017: Cambrex invests $24 million in new highly potent API manufacturing capacity at its Charles City, Iowa facility 17
Financial Announcements 18
Aug 02, 2018: Cambrex reports second quarter 2018 financial results 18
May 03, 2018: Cambrex Reports First Quarter 2018 Financial Results 20
Feb 08, 2018: Cambrex Reports Fourth Quarter and Full Year 2017 Financial Results 22
Nov 07, 2017: Cambrex Reports Third Quarter 2017 Financial Results 24
May 04, 2017: Cambrex Reports First Quarter 2017 Financial Results 26
Feb 03, 2017: Cambrex Reports Fourth Quarter and Full Year 2016 Financial Results 28
Corporate Communications 30
Nov 03, 2017: Gregory B. Brown M.D. Appointed to the Board of Directors of Cambrex Corporation 30
Jan 04, 2017: Cambrex Appoints Tom Vadaketh as Executive Vice President and Chief Financial Officer 31
Other Significant Developments 32
Jun 12, 2018: Cambrex Expands Generic API Research and Development Capabilities at Milan, Italy Site 32
May 31, 2018: Cambrex Invests $5 Million in New Laboratory Expansion at its Karlskoga, Sweden Facility 33
Apr 23, 2018: Cambrex Completes New $3.2 Million Analytical Research & Development Laboratory at its High Point, NC Facility 34
Apr 17, 2018: Cambrex Invests in New Continuous Flow Technology at its High Point, NC Facility 35
Jan 30, 2018: Cambrex Expands Process Research and Development Capabilities Across North America 36
Oct 12, 2017: Cambrex Invests in Generic API Development and Manufacturing Capabilities at Its Milan Site 37
Aug 30, 2017: Cambrex Invests in New Analytical Development and Method Validation Laboratory at Its High Point, NC Facility 38
Aug 08, 2017: Cambrex invests $24 million in new highly potent API manufacturing capacity at its Charles City, Iowa facility 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Cambrex Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cambrex Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cambrex Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cambrex Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Cambrex to Acquire Halo Pharma from SK Capital Partners for USD425 Million 9
Cambrex Acquires PharmaCore for USD24.275 Million 11
Cambrex Acquires 100% Stake in Zenara Pharma 12
Cambrex Corp, Key Competitors 13
Cambrex Corp, Key Employees 14
Cambrex Corp, Other Locations 15
Cambrex Corp, Subsidiaries 15

List of Figures
Cambrex Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cambrex Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

★調査レポート[Cambrex Corp (CBM):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C5330)販売に関する免責事項を必ずご確認ください。
★調査レポート[Cambrex Corp (CBM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆